Photodiagnosis and Photodynamic Therapy最新文献

{"title":"Associations between choroidal thickness and rate of axial elongation in orthokeratology lens users","authors":"Riping Zhang ,&nbsp;Suoqing Zhuang ,&nbsp;Youming Zhou ,&nbsp;Man Pan Chin ,&nbsp;Lixia Sun ,&nbsp;Vishal Jhanji ,&nbsp;Mingzhi Zhang","doi":"10.1016/j.pdpdt.2024.104450","DOIUrl":"10.1016/j.pdpdt.2024.104450","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the impact of using orthokeratology lenses (OK lenses) for one year on the axial length (AL) and choroidal thickness (ChT) in the 6 mm concentric central retinal region.</div></div><div><h3>Methods</h3><div>36 myopic children (36 eyes) aged 8 to 16 years were enrolled. For the duration of one year, the OK group (18 subjects) utilized OK lenses, while the spectacles group (18 subjects) utilized single-vision spectacles as a control. Only their right eyes were used for analysis. ChT in nine regions of the retina was evaluated using optical coherence tomography. AL and other ocular parameters were measured using optical biometry. The measurements were obtained at baseline, 3 months, 6 months, and 12 months.</div></div><div><h3>Results</h3><div>After 12 months of treatment, the OK group showed a reduced rate of AL elongation. The first interval (baseline to 3 months) saw the most notable alteration (<em>p</em> &lt; 0.0001). ChT increased in most regions after wearing OK lenses, except for the nasal retinal region. However, the alteration in nasal ChT exhibited the strongest association with the alteration in AL.</div></div><div><h3>Conclusion</h3><div>The efficacy of myopia control with OK lenses is most pronounced during the initial months of wear. Alterations in the thickness of the nasal choroidal region may correlate with the elongation of the AL, implying its potential role as a biomarker for assessing the efficacy of OK lenses in myopia control.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104450"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematoporphyrin derivative-photodynamic therapy (HpD-PDT) for extensive vulvar and vaginal Bowen's disease: A case report","authors":"Xiaoqing Xiang ,&nbsp;Yanliang Li ,&nbsp;Can Shi ,&nbsp;Runqun Liu ,&nbsp;Guozhang Ma ,&nbsp;Yunyun Cao ,&nbsp;Lianheng Xia ,&nbsp;Jie Gao","doi":"10.1016/j.pdpdt.2024.104465","DOIUrl":"10.1016/j.pdpdt.2024.104465","url":null,"abstract":"<div><div>Bowen's disease (BD) is an intraepithelial squamous cell carcinoma (SCC) that commonly affects older individuals, with the vulva being a prevalent site in women. Lesions within the vagina pose a particular challenge for surgical treatment, often compromising both functional integrity and cosmesis. Photodynamic therapy (PDT) is an emerging, safe, and non-invasive technique utilizing a photosensitizer and a specific light source, widely applied in the treatment of malignancies and skin diseases. We report the case of a 74-year-old woman presenting with a large, dark brown patch on the vulva, histopathologically confirmed as BD. The patient also had lesions within the vagina. Hematoporphyrin derivative-photodynamic therapy (HpD-PDT) was administered, with an optical fiber used for targeted treatment of the vaginal lesions. Complete resolution of the lesions was observed after a single treatment. A follow-up biopsy at 7 months post-treatment revealed no residual tumor cells. The patient remains disease-free at 2 years follow-up and continues to be monitored. This case suggests that HpD-PDT is a viable treatment option for BD, and may be particularly advantageous for elderly patients with extensive or vaginally located lesions, where preserving function and cosmesis is paramount.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104465"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optic nerve head changes in acute central serous chorioretinopathy: Implications for glaucoma risk","authors":"Esma Ecem Ersoy,&nbsp;Ebubekir Durmuş","doi":"10.1016/j.pdpdt.2025.104478","DOIUrl":"10.1016/j.pdpdt.2025.104478","url":null,"abstract":"<div><h3>Objective</h3><div>Imaging techniques have demonstrated changes in the choroid and retina in acute central serous chorioretinopathy (CSCR), but the effects on the optic nerve head (ONH) remain unclear. This study investigates ONH structural changes in acute CSCR using enhanced deep imaging optical coherence tomography (EDI-OCT).</div></div><div><h3>Methods</h3><div>A prospective cohort study included 51 acute CSCR patients and 51 healthy controls aged 18–65 years. Patients had symptoms for less than three months, with no prior treatment or ocular pathology. Participants with refractive errors of ±6D spherical or less and ±3D cylindrical or less were included, while with optic nerve/choroidal conditions, corticosteroid use, systemic diseases like sleep apnea, and media opacities were excluded. Comprehensive eye exams and EDI-OCT were performed to evaluate retinal, choroidal, and ONH parameters.</div></div><div><h3>Results</h3><div>The mean subfoveal choroidal thickness (SFCT) (434.51±95.45 µm vs. 289.55±87.21 µm) and peripapillary choroidal thickness (PPCT) (282.12±79.14 µm vs. 180.79±53.99 µm) were significantly higher in the CSCR group compared to controls (<em>p</em> &lt; 0.001 for both). Retinal nerve fiber layer (RNFL) (107.14±15.15 µm vs. 101.06±14.31 µm, <em>p</em> = 0.04) and lamina cribrosa thickness (LCT) (307.14±63.83 µm vs. 200.04±54.23 µm, <em>p</em> &lt; 0.001) were significantly higher, while anterior laminar depth (ALD) and Bruch's membran opening-minimum rim width (BMO-MRW) were significantly lower in the acute CSCR.</div></div><div><h3>Conclusion</h3><div>In acute CSCR, increased SFCT is accompanied by a corresponding rise in PPCT, leading to significant ONH structural changes and enhanced blood flow, potentially offering glaucoma protection. However, further research is needed to explore the long-term effects of chronic CSCR on choriocapillaris ischemia and optic nerve.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104478"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema","authors":"Kai Ching Peter Leung,&nbsp;Sunny, Chi Lik Au","doi":"10.1016/j.pdpdt.2025.104484","DOIUrl":"10.1016/j.pdpdt.2025.104484","url":null,"abstract":"","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104484"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life","authors":"L Bernal-Masferrer ,&nbsp;T Gracia-Cazaña ,&nbsp;L Najera-Botello ,&nbsp;MC Gomez-Mateo ,&nbsp;P Cerro ,&nbsp;MC Matei ,&nbsp;M Gallego-Rentero ,&nbsp;S González ,&nbsp;A Juarranz ,&nbsp;Y Gilaberte","doi":"10.1016/j.pdpdt.2024.104442","DOIUrl":"10.1016/j.pdpdt.2024.104442","url":null,"abstract":"<div><h3>Background</h3><div>Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study investigates the clinical, histological, and molecular factors that affect the efficacy of methyl aminolevulinate PDT (MAL-PDT) for BCC and BD.</div></div><div><h3>Methods and Patients</h3><div>Prospective observational multicentric study performed between May 2019 and January 2021 with 64 patients included. Clinical data such as tumor thickness, location, and histological subtype were recorded. Immunohistochemical analysis was performed on tumor samples to assess the expression of biomarkers including p53, β-catenin, and GLUT1.</div></div><div><h3>Results</h3><div>Tumor thickness was found to be a critical determinant of MAL-PDT response, with thicker nodular BCCs showing reduced response rates compared to thinner, superficial BCCs and BD lesions. Immunohistochemical analysis revealed that p53 positivity was associated with better treatment outcomes, while increased β-catenin and cytoplasmic GLUT1 expression correlated with resistance to PDT. On the other hand, the metabolic profile of the tumors indicated that tumors with higher glycolytic activity were less responsive to treatment, therefore, using metformin, a glycolytic inhibitor, as a potential adjuvant therapy to improve outcomes in resistant tumors should be considered.</div></div><div><h3>Conclusion</h3><div>This study emphasizes the importance of personalized approaches in the use of MAL-PDT, tailoring treatment according to tumor-specific characteristics. Biomarkers such as p53, β-catenin, and GLUT1 can serve as predictive tools for PDT response, helping clinicians identify patients who may benefit from alternative or combined treatments to enhance therapeutic efficacy.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104442"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Umbrella review of adjuvant photodynamic therapy for cholangiocarcinoma palliative treatment","authors":"Hanhan Chen ,&nbsp;Honglin Li ,&nbsp;Huijie Li ,&nbsp;Zhen Zhang","doi":"10.1016/j.pdpdt.2025.104472","DOIUrl":"10.1016/j.pdpdt.2025.104472","url":null,"abstract":"<div><h3>Background</h3><div>Cholangiocarcinoma is a rare and often fatal malignancy. Numerous studies have demonstrated promising outcomes and survival rates associated with adjuvant photodynamic therapy (PDT) in the palliative treatment of cholangiocarcinoma.</div></div><div><h3>Objective</h3><div>To systematically evaluate the existing meta-analyses on PDT for cholangiocarcinoma, assessing evidence quality and strength while performing updated meta-analyses to refine survival outcomes.</div></div><div><h3>Methods</h3><div>PubMed, EMBASE, Cochrane Library, and Web of Science were systematically searched up to September 18, 2024, to identify meta-analyses and clinical studies on PDT in patients with cholangiocarcinoma. The random-effects model was employed to re-synthesize existing meta-analyses, with a comprehensive evaluation of methodological quality. Updated meta-analyses of survival data were conducted, including subgroup analyses stratified by cholangiocarcinoma type and intervention modality.</div></div><div><h3>Results</h3><div>A total of 5 meta-analyses and 21 clinical studies were included. The findings indicated that combining PDT with stenting or chemotherapy can significantly improve overall survival in patients with cholangiocarcinoma and reduce mortality rate, without increasing the risk of adverse events (AEs) such as cholangitis or abscess formation. For extrahepatic cholangiocarcinoma, adding PDT to stenting demonstrated a notable improvement in the 2-year survival rate. Meanwhile, for hilar cholangiocarcinoma, the addition of chemotherapy to PDT showed a more pronounced enhancement in the 1-year survival rate.</div></div><div><h3>Conclusion</h3><div>Current evidence indicates that PDT combined with stenting or chemotherapy in the palliative treatment of cholangiocarcinoma decreases overall mortality and enhances OS without increasing the incidence of AEs. Adding PDT to stenting or chemotherapy may be more beneficial for long-term efficacy.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104472"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical riboflavin versus 5-aminolevulinic acid photodynamic therapy for the treatment of mild to moderate acne: A split-face randomized study","authors":"Aijia Ding ,&nbsp;Li Shi ,&nbsp;Feng Jiang ,&nbsp;Chong Wang ,&nbsp;Jianglin Zhang","doi":"10.1016/j.pdpdt.2024.104449","DOIUrl":"10.1016/j.pdpdt.2024.104449","url":null,"abstract":"<div><h3>Background</h3><div>ALA-PDT has been widely used in mild to moderate acne vulgaris worldwide. However, very few studies used riboflavin-PDT to treat acne vulgaris.</div></div><div><h3>Objective</h3><div>To investigate the efficacy and adverse events of riboflavin-PDT to treat mild to moderate facial acne, and compare it with ALA-PDT on a non-inferiority basis.</div></div><div><h3>Methods</h3><div>33 eligible patients were enrolled, and 30 patients completed follow-up. Either side of the face was assigned randomly to riboflavin or ALA blue-light-PDT. Patients received 3 sessions of PDT in 1-week intervals and were followed up at weeks 4, 6, and 10.</div></div><div><h3>Results</h3><div>Both ALA and riboflavin-PDT significantly reduced non-inflammatory and inflammatory lesions at weeks 4, 6, and 10 compared to baseline (P all &lt;0.001). For the primary outcome, the difference in the improvement rate of total lesions between the Ribo and ALA side was 2.6 % (-4.3 %, 12.5 %; <em>p</em> = 0.71), which didn't reach the inferiority margin. Patients described greater in-treatment pain and burning sensation (<em>P</em> &lt; 0.001), more prominent post-treatment erythema (<em>P</em> = 0.003), hyperpigmentation (<em>P</em> &lt; 0.001), and desquamation (<em>P</em> = 0.006) on the ALA side than on riboflavin side.</div></div><div><h3>Conclusion</h3><div>The efficacy of riboflavin-PDT was comparable to that of blue-light ALA-PDT in treating mild to moderate acne vulgaris. Riboflavin-PDT had fewer in-treatment and post-treatment adverse events than ALA-PDT.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104449"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroidal vascular parameters in ocular rosacea patients","authors":"Mariagrazia Avella,&nbsp;Isabella Pellegrino","doi":"10.1016/j.pdpdt.2024.104468","DOIUrl":"10.1016/j.pdpdt.2024.104468","url":null,"abstract":"","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104468"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of photodynamic therapy on vaginal intraepithelial neoplasia grade one: A retrospective cohort study","authors":"Yao Yang ,&nbsp;Dan Cao ,&nbsp;Yi Chen,&nbsp;Ying Xu,&nbsp;Zhenhong Xiong,&nbsp;Zhengrong Zhang,&nbsp;Dan Wu","doi":"10.1016/j.pdpdt.2025.104486","DOIUrl":"10.1016/j.pdpdt.2025.104486","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy of photodynamic therapy (PDT) for vaginal intraepithelial neoplasia grade 1 (VaIN1) related to high-risk (Hr)-human papillomavirus (HPV).</div></div><div><h3>Methods</h3><div>Participants aged 25–65 years treated for VaIN1 between March 2022 and September 2022 were retrospectively analyzed into three groups. The PDT and follow-up groups were matched 1:1 for gravidity, HPV type, and quadrants involved. The PDT and CO₂ laser groups were compared without matching. Patients were followed up at 6, 12, and 24 months.</div></div><div><h3>Results</h3><div>After matched, the lesion and Hr-HPV clearance rates of the PDT group (89.5%, 89.5%, 92.1%, and 81.6%, 84.2%, 89.5%) were significantly higher than those of the follow-up group (31.6%, 50.0%, 63.2%, and 21.1%, 26.3%, 31.6%, <em>P</em> &lt; 0.05) at 6, 12, and 24 months. But the lesion clearance rates did not differ significantly between the PDT (68.9%, 82.2%, and 91.1%) and CO₂ laser groups (68.7%, 78.3%, and 85.5%, <em>P</em> &gt; 0.05) at 6, 12, and 24 months, and so did Hr-HPV clearance rates (PDT as 62.2% and 77.8%, and CO₂ laser 54.2% and 61.4%, respectively, <em>P</em> &gt; 0.05) at 6 and 12 months. However, at 24 months, the Hr-HPV clearance rate was higher in the PDT group than in the CO₂ laser group (86.7% vs 71.1%, <em>P</em> = 0.047). In the PDT group, none of the lesions progressed.</div></div><div><h3>Conclusions</h3><div>Compared with CO₂ laser, PDT resulted in a higher Hr-HPV clearance, as well as a low risk of complications and disease progression. PDT is an effective and noninvasive treatment for VaIN1.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104486"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"‘Photodynamic therapy light’: An enhanced treatment protocol for actinic keratoses with minimal pain and optimal clinical outcome by combining laser-assisted low irradiance PDT with shortened daylight PDT","authors":"Martin T. Braun ,&nbsp;Kelly Del Tredici ,&nbsp;Anna Wölling ,&nbsp;Luitgard Wiest","doi":"10.1016/j.pdpdt.2024.104372","DOIUrl":"10.1016/j.pdpdt.2024.104372","url":null,"abstract":"<div><h3>Background</h3><div>Between 2003 and 2016, 546 patients in our clinic discontinued outpatient treatment for actinic keratoses (AKs) using conventional photodynamic therapy (PDT) because of intolerable pain, thereby necessitating the use of a less painful procedure. Therefore, we developed a novel off-label PDT protocol: ‘PDT light’.</div></div><div><h3>Methods</h3><div>Laser-assisted low irradiance PDT (li-PDT) was performed beginning in 2014. The dosage was gradually lowered to 8–12 <em>J</em>/cm² in 2018, so that we achieved considerable pain reduction while maintaining comparable therapeutic efficacy. A further considerable reduction in pain was achieved from 2018 onwards by combining the advantages of li-PDT with daylight PDT (DLPDT), thereby resulting in 2018 in the new technique ‘PDT light’. Patients with AK Olsen grades 1 or 2 and field cancerization initially received a mild-fractionated CO2 laser pretreatment prior to MAL-incubation (methyl aminolaevulinate, Metvix ®) under occlusion for 1.5–3 h. Then, patients were illuminated on average for 1.02 min with the Aktilite-LED and, after application of an UV-screen on the illuminated area, sent out into daylight for 1 h.</div></div><div><h3>Results</h3><div>Between March and November 2019, we successfully treated 152 cases using the enhanced ‘PDT light’ procedure, with 137 cases achieving at follow-up 1 (on average after 8.14 months) good-to-excellent clearance rates (CLA and CLB together 90 %) and minimal adverse effects.</div></div><div><h3>Conclusions</h3><div>The novel ‘PDT light’ protocol proved to be an excellent and nearly painless method with an average visual-analogue scale (VAS) score of 1.19. Additional advantages included reduced illumination time, shorter outpatient stays in the clinic, fewer adverse effects, and better patient compliance than with DLPDT alone.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104372"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}